Colchicine-Associated Hypoglycemia in Diabetic Dialysis Patients: Observations from a Tanzanian Dialysis Unit: A Case Reports
Authors
Keywords:
- Dialysis,
- Gout,
- Cholchicine,
- Hypoglycemia,
- Diabetes
Abstract
Background: Colchicine is widely used for the treatment of acute gout flares due to its anti-inflammatory properties. Beyond this traditional role, colchicine has been implicated in modulating various physiological systems, including glucose metabolism. Notably, it exhibits a biphasic effect on blood glucose levels causing hypoglycemia at lower doses and hyperglycemia at higher doses. However, its impact on glycemic control in diabetic patients undergoing dialysis remains poorly characterized.
Case report: We report two cases from the Dialysis Unit at Kilimanjaro Christian Medical Centre (KCMC) in northern Tanzania involving two Black African diabetic males aged 66 and 62 years with End-Stage Renal Disease (ESRD) on maintenance hemodialysis. Both patients experienced a notable and reproducible decline in blood glucose levels following colchicine administration for gout flares. The hypoglycemia occurred in the absence of other identifiable precipitating factors and resolved upon withholding colchicine.
Discussion: These observations raise important questions regarding the potential glucose-lowering effects of colchicine in dialysis dependent diabetic patients. The exact mechanism remains unclear but may involve colchicine’s influence on insulin sensitivity, hepatic glucose production or inflammatory pathways that indirectly affect glucose metabolism. Given the already high risk of hypoglycemia in ESRD patients, these findings warrant careful consideration and further investigation.
Conclusion: Colchicine may have an under recognized hypoglycemic effect in diabetic patients undergoing dialysis. Clinicians should be alert to this potential interaction, particularly in patients with poor glycemic reserve. Further research is needed to elucidate the mechanisms involved and assess whether colchicine could be repurposed as an adjunctive agent for glycemic control in selected ESRD populations.
Downloads
References
Terkeltaub RA (2009) Colchicine update: 2008. Semin Arthritis Rheum 38: 411-419. https://www.sciencedirect.com/science/article/abs/pii/S0049017208001534?via%3Dihub
Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos G, Cleman M, et al. (2020) Colchicine in cardiovascular medicine. Eur Heart J 41: 2325-2329.
Nidorf SM, Thompson PL (2007) Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein and interleukin-6 in patients with stable coronary artery disease. Am J Cardiol 99: 1465-1468. https://www.ajconline.org/article/S0002-9149(06)02370-8/abstract
Rimar D, Rosner I (2007) Drug-induced hypoglycemia: An overlooked cause of hypoglycemia. QJM 100: 565-569.
Shlomai G, Kopel E, Goldenberg I, Grossman E (2014) Colchicine-induced hypoglycemia in a dialysis patient. Nephrol Dial Transplant 29: 1774.
Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, et al. (2018) Colchicine: An ancient drug with novel applications. Br J Dermatol 178: 350-356. https://academic.oup.com/bjd/article-abstract/178/2/350/6732128?redirectedFrom=fulltext&login=false
Wolf G, Ritz E (2003) Diabetic nephropathy: Clinical considerations. Kidney Int Suppl 63: S39-S45.
Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, et al. (2009) Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 4: 1121-1127. https://journals.lww.com/cjasn/abstract/2009/06000/frequency_of_hypoglycemia_and_its_significance_in.16.aspx
Tardif JC, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, et al. (2021) Colchicine for community-treated patients with COVID-19 (COLCORONA): A phase 3, randomised, double-blind, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 9: 924-932. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00222-8/fulltext
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake and the risk of gout in men. N Engl J Med 350: 1093-1103. https://www.nejm.org/doi/full/10.1056/NEJMoa035700
Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, et al. (2015) Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 74: 1561-1568. https://ard.eular.org/article/S0003-4967(24)18813-9/abstract
Nidorf M, Thompson PL, Low LP (2020) Why colchicine should be considered for secondary prevention of atherosclerosis. Eur Heart J 41: 3097-3102. https://www.clinicaltherapeutics.com/article/S0149-2918(18)30596-4/fulltext
